Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
13505 | 768 | 41.3 | 94% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | FRACTALKINE | Author keyword | 181 | 64% | 23% | 178 |
2 | CXCL16 | Author keyword | 67 | 72% | 7% | 52 |
3 | CX3CR1 | Author keyword | 64 | 48% | 13% | 98 |
4 | CX3CL1 | Author keyword | 55 | 62% | 7% | 57 |
5 | CXCR6 | Author keyword | 49 | 82% | 4% | 28 |
6 | SR PSOX | Author keyword | 12 | 86% | 1% | 6 |
7 | FRACTALKINE CX3CL1 | Author keyword | 11 | 78% | 1% | 7 |
8 | FRACTALKINE RECEPTOR | Author keyword | 9 | 67% | 1% | 8 |
9 | CHEMOKINE CX3CL1 | Author keyword | 4 | 75% | 0% | 3 |
10 | CELLULAR GENE THER IES HFM518 | Address | 3 | 100% | 0% | 3 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | FRACTALKINE | 181 | 64% | 23% | 178 | Search FRACTALKINE | Search FRACTALKINE |
2 | CXCL16 | 67 | 72% | 7% | 52 | Search CXCL16 | Search CXCL16 |
3 | CX3CR1 | 64 | 48% | 13% | 98 | Search CX3CR1 | Search CX3CR1 |
4 | CX3CL1 | 55 | 62% | 7% | 57 | Search CX3CL1 | Search CX3CL1 |
5 | CXCR6 | 49 | 82% | 4% | 28 | Search CXCR6 | Search CXCR6 |
6 | SR PSOX | 12 | 86% | 1% | 6 | Search SR+PSOX | Search SR+PSOX |
7 | FRACTALKINE CX3CL1 | 11 | 78% | 1% | 7 | Search FRACTALKINE+CX3CL1 | Search FRACTALKINE+CX3CL1 |
8 | FRACTALKINE RECEPTOR | 9 | 67% | 1% | 8 | Search FRACTALKINE+RECEPTOR | Search FRACTALKINE+RECEPTOR |
9 | CHEMOKINE CX3CL1 | 4 | 75% | 0% | 3 | Search CHEMOKINE+CX3CL1 | Search CHEMOKINE+CX3CL1 |
10 | CX3CL1 FRACTALKINE | 3 | 60% | 0% | 3 | Search CX3CL1+FRACTALKINE | Search CX3CL1+FRACTALKINE |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CX3CR1 | 124 | 65% | 15% | 117 |
2 | RECEPTOR CX3CR1 | 113 | 71% | 12% | 92 |
3 | CHEMOKINE FRACTALKINE | 69 | 81% | 5% | 42 |
4 | SR PSOX | 67 | 78% | 6% | 45 |
5 | MEMBRANE BOUND CHEMOKINE | 66 | 79% | 5% | 42 |
6 | CXCL16 SR PSOX | 65 | 95% | 3% | 21 |
7 | CHEMOKINE LIGAND 16 | 41 | 85% | 3% | 22 |
8 | FRACTALKINE RECEPTOR CX3CR1 | 39 | 53% | 7% | 52 |
9 | CX3CL1 FRACTALKINE | 32 | 88% | 2% | 15 |
10 | SOLUBLE FRACTALKINE | 31 | 82% | 2% | 18 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Microglia, seen from the CX(3)CR1 angle | 2013 | 37 | 66 | 38% |
Transmembrane chemokines: Versatile 'special agents' in vascular inflammation | 2007 | 70 | 120 | 68% |
Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential | 2010 | 46 | 93 | 60% |
Fractalkine/CX3CR1 and atherosclerosis | 2011 | 21 | 65 | 83% |
Therapeutic potential of the chemokine-receptor duo fractalkine/CX3CR1: an update | 2012 | 15 | 34 | 65% |
Role of Fractalkine/CX3CL1 and Its Receptor in the Pathogenesis of Inflammatory and Malignant Diseases with Emphasis on B Cell Malignancies | 2014 | 3 | 90 | 67% |
Fractalkine in vascular biology - From basic research to clinical disease | 2004 | 159 | 80 | 53% |
Fractalkine/CX3CR1 signaling during neuropathic pain | 2014 | 3 | 67 | 54% |
Genetic diversity of CX3CR1 gene and coronary artery disease: New insights through a meta-analysis | 2009 | 20 | 26 | 73% |
CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer | 2010 | 35 | 76 | 50% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CELLULAR GENE THER IES HFM518 | 3 | 100% | 0.4% | 3 |
2 | U543 | 2 | 12% | 1.8% | 14 |
3 | GENE EXP S PROT CHEM | 1 | 100% | 0.3% | 2 |
4 | PHARMACOL TOXICOL RWTH | 1 | 100% | 0.3% | 2 |
5 | ECCELLENZA BEMM | 1 | 22% | 0.7% | 5 |
6 | BYRD ALZHEIMER | 1 | 40% | 0.3% | 2 |
7 | RHEUMATOLSHINAGAWA KU | 1 | 40% | 0.3% | 2 |
8 | NEUROTHER EUT GRP | 1 | 33% | 0.3% | 2 |
9 | AFFILIATED YUE BEI PEOPLES HOSP | 1 | 50% | 0.1% | 1 |
10 | ALS UNITNEUROL | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000134921 | IMMUNOBIOL ROBERT H LURIE CANC//EXPT CLIN NEUROL//MS CLIN |
2 | 0.0000134260 | MONOCYTE CHEMOATTRACTANT PROTEIN 1//MCP 1 POLYMORPHISM//REGULATED UPON ACTIVATION |
3 | 0.0000118584 | MONOCYTE SUBSETS//MONOCYTE HETEROGENEITY//MONOCYTE SUBSET |
4 | 0.0000113023 | CCR2 ANTAGONIST//CCR2//CCR2 ANTAGONISTS |
5 | 0.0000077395 | THYMUS AND ACTIVATION REGULATED CHEMOKINE//TARC//CCR4 |
6 | 0.0000072922 | CXCR4//CXCR7//CXCL12 |
7 | 0.0000070724 | CD4CD28 T CELLS//CD4CD28NULL T CELLS//CD4CD28NULL CELLS |
8 | 0.0000065614 | CXCR3//CXCL10//CXCL9 |
9 | 0.0000062011 | CCL20//CCR6//MACROPHAGE INFLAMMATORY PROTEIN 3 ALPHA |
10 | 0.0000060115 | LYMPHOTACTIN//CTAP III//CHEMOKINE STRUCTURE |